{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:31:38Z","timestamp":1774045898233,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neuropharm.2018.08.024","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T02:59:46Z","timestamp":1534993186000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Psychedelics \u2013 Re-opening the doors of perception"],"prefix":"10.1016","volume":"142","author":[{"given":"David J.","family":"Heal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno G.","family":"Frenguelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.08.024_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","article-title":"Regulation of human research with LSD in the United States (1949-1987)","volume":"235","author":"Bonson","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuropharm.2017.11.045","article-title":"NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update","volume":"142","author":"Cadinu","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2017.11.028","article-title":"A regulatory perspective on the evaluation of hallucinogen drugs for human use","volume":"142","author":"Calderon","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuropharm.2018.03.010","article-title":"The entropic brain - revisited","volume":"142","author":"Carhart-Harris","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","article-title":"The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs","volume":"8","author":"Carhart-Harris","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib7","article-title":"Assessment of Abuse Potential of Drugs","author":"CDER\/FDA, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2017.12.023","article-title":"The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders","volume":"142","author":"Collins","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","article-title":"A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study","volume":"142","author":"Dakwar","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuropharm.2017.10.004","article-title":"TCB-2 [(7R)-3-bromo-2,5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: a hallucinogenic drug, a selective 5-HT(2A) receptor pharmacological tool, or none of the above?","volume":"142","author":"Di Giovanni","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neuropharm.2018.02.033","article-title":"Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats","volume":"142","author":"Elmore","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms","volume":"142","author":"Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","article-title":"How LSD originated","volume":"11","author":"Hofmann","year":"1979","journal-title":"J. Psychedelic Drugs"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib17","series-title":"LSD - My Problem Child","isbn-type":"print","author":"Hofmann","year":"1980","ISBN":"https:\/\/id.crossref.org\/isbn\/0070293252"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neuropharm.2018.06.008","article-title":"Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity","volume":"142","author":"Ingram","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2016","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neuropharm.2018.06.034","article-title":"Positive psychology in the investigation of psychedelics and entactogens: a critical review","volume":"142","author":"Jungaberle","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neuropharm.2018.02.028","article-title":"Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs","volume":"142","author":"Klein","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib26","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1021\/jm060656o","article-title":"1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists","volume":"49","author":"McLean","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib27","unstructured":"Neuropharmacology Special Issue on Designer Drugs and Legal Highs https:\/\/www.sciencedirect.com\/journal\/neuropharmacology\/vol\/134\/part\/PA."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuropharm.2017.11.049","article-title":"The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: regionally-selective involvement of 5-HT1A and 5-HT2A receptors","volume":"142","author":"Riga","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression","volume":"142","author":"Roseman","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/cpt.697","article-title":"Psilocybin: good trip or bad trip","volume":"102","author":"Sellers","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/cpt.776","article-title":"Psychedelic drugs as therapeutics: no illusions about the challenges","volume":"103","author":"Sellers","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2017.11.029","article-title":"Studies with psychedelic drugs in human volunteers","volume":"142","author":"Sellers","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.115.228148","article-title":"Directly observable behavioral effects of lorcaserin in rats","volume":"355","author":"Serafine","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jeab.222","article-title":"Characterization of the discriminative stimulus effects of lorcaserin in rats","volume":"106","author":"Serafine","year":"2016","journal-title":"J. Exp. Anal. Behav."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neuropharm.2017.11.004","article-title":"Why MDMA therapy for alcohol use disorder? And why now?","volume":"142","author":"Sessa","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.024_bib37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/clpt.2011.20","article-title":"Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users","volume":"89","author":"Shram","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.neuropharm.2018.08.024_bib38","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0376-8716(03)00096-6","article-title":"Keeping the lid on: a century of drug regulation and control","volume":"70","author":"Spillane","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.08.024_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2017.10.039","article-title":"LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm","volume":"142","author":"Timmermann","year":"2018","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818305549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818305549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T13:05:07Z","timestamp":1558011907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818305549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":39,"alternative-id":["S0028390818305549"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.08.024","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelics \u2013 Re-opening the doors of perception","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}